恒瑞医药H股大涨近30% 公开发售阶段获454.85倍认购

Group 1 - The core point of the article highlights that Heng Rui Pharmaceutical (01276.HK) has seen a significant stock increase of 29.40% [1] - The company experienced a subscription rate of 454.85 times during the public offering phase [1] - In the international placement phase, the subscription rate was 17.09 times [1]